Neurorehabilitation News

Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.

A collaboration between Mayo Clinic researchers and a team dedicated to researching frontotemporal dementia has identified neurofilament light as a useful biomarker for the disease.

Veteran patients and health care providers felt complementary and integrative medicine was a safe addition to mainstream treatment options for headache management, researchers reported in BMC Complementary Medicine and Therapies.

Former college football players had a significantly higher prevalence of several health issues later in life than nonplayers, according to findings published in JAMA Network Open.

SEATTLE – Inebilizumab was shown to be safe and effective in preventing relapses in individuals with neuromyelitis optica spectrum disorder, a speaker said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Although successful tau therapeutics have not yet been identified, new insights into the protein’s biology may soon lead to treatments, according to a presenter at the 2022 American Academy of Neurology annual meeting.

SEATTLE — The use of 30 mg per day of zolpidem may significantly improve quality of life among patients with prolonged disorders of consciousness, a presenter said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Full recovery and functional independence is possible in patients who experience a disorder of consciousness after severe COVID-19 infection, according to a presenter at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Sage Therapeutics will be starting a randomized, controlled trial in patients with Alzheimer’s disease, Aaron Koenig, MD, the company’s vice president of early clinical development, said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — People with persistent cognitive symptoms after mild COVID-19 infection had elevated cerebrospinal fluid inflammatory markers, according to a presentation at the 2022 American Academy of Neurology annual meeting.